Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab

Phase 4 Unknown 203 enrolled Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, longitudinal, multicenter study conducted in a cohort of patients with early CD. This study will not change the patient/physician relationship.

Timeline

Start: 2015-03-17
Primary completion: 2021-03
Completion: 2025-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Adalimumab	Monoclonal antibody	40 mg	—

Indications

No indication recorded.